Table 5.
Characteristics of Patients With AIH and Features of Disease Relapse During COVID‐19
| Case | Sex | Age at COVID‐19 | Diagnosis | Response at Last Visit | Therapy During COVID‐19 | Care for COVID‐19 | ALT/IgG (×ULN) | Management/Response |
|---|---|---|---|---|---|---|---|---|
| 1 | F | 60 | AIH | Complete | Azathioprine, 50 mg/day, Prednisolone, 5 mg/day | Home | 6.9/1.1 | Azathioprine and prednisolone increased/Yes |
| 2 | F | 52 | AIH | Complete | MMF, 1,000 mg/day, Prednisolone, 10 mg/day | Hospital, 5 days, no O2 therapy | 6.8/1.7 | MMF switched to tacrolimus/Yes |
| 3 | F | 44 | AIH | Complete | In remission without therapy | Home | 4.3/1.2 | Azathioprine and prednisolone added/Yes |
| 4 | F | 51 | AIH/PBC | Complete | Prednisolone, 5 mg/day, UDCA, 750 mg/day | Hospital, 6 days, nasal O2 | 4.8/1.2 | Prednisolone increased/Yes |
Abbreviation: UDCA, ursodeoxycholic acid.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.